Other substances

C1632

An experimental anti-inflammatory and anti-coronaviral drug.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

C1632 is a drug which has been shown to promote maturation of let-7 miRNA. It was observed to suppress cytokine inflammatory response through this activity.  C1632-promoted let-7 activity was experimentally shown to impede SARS-CoV-2 replication via M and S protein levels reduction (Xie et al., 2021).

C1632 on PubChem

Synonyms

N-Methyl-N-[3-(3-methyl[1,2,4]triazolo[4,3-b] pyridazin-6-yl)phenyl]acetamide; Lin281632

 

Structure image - C1632

CC1=NN=C2N1N=C(C=C2)C3=CC(=CC=C3)N(C)C(=O)C

Supporting references

Link Tested on Impact factor Notes Publication date
Therapeutic potential of C1632 by inhibition of SARS-CoV-2 replication and viral-induced inflammation through upregulating let-7
Small molecule In vitro Mechanism 		HEK293T cells; A549 cells; Huh-7 cells; THP1 cells; peripheral blood mononuclear cells; SARS-CoV-2 live virus (GeneBank accession no. MT123290.1) 13.49

The drug promoted let-7 miRNA maturation, which let to decreased pro-inflammatory cytokine production in vitro. let-7 upregulation also suppressed SARS-CoV-2 M and S protein levels, which reduced viral replication.

 Feb/22/2021
Export (.csv)